Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Sagimet Biosciences Inc.NASDAQ: SGMT
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $1.61M, compared with -$11.12M a year earlier. Trailing-twelve-month net change in cash was -$28.09M. Over 3 fiscal years it compounded at -10.3% a year.
Context
- Net change in cash increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near $1.61M or moves back toward the trailing-twelve-month quarterly average of -$7.02M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (40.82M) USD
- Year-over-year change
- -5923.0%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (40.82M) | -5923.0% |
| FY2024 | 2024-12-31 | 701K | -99.1% |
| FY2023 | 2023-12-31 | 74.98M | +232.5% |
| FY2022 | 2022-12-31 | (56.57M) | -372.6% |
| FY2021 | 2021-12-31 | (11.97M) | — |
Net Change in Cash vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 net change in cash of $28.09M is the 6th largest of the 11 companies compared; the peer median is $7.83M.
- Its year-over-year change of -74.9% is the lowest of 11, against a peer median of +96.7%.
- Over three fiscal years its annual growth of -10.3% compares with a peer median of -21.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.45M | +2324.8% | -13.1% | 3197.0% | |
| LTM Mar 2026 | $60.43M | -15.4% | — | 133.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $55.03M | -31.9% | — | — |
| LTM Mar 2026 | $40.08M | -3.5% | — | — | |
| LTM Mar 2026 | $34.32M | -49.8% | -30.5% | 94.0% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $28.09M | -74.9% | -10.3% | — |
| LTM Mar 2026 | $27.89M | +253.0% | — | 98.8% | |
| LTM Mar 2026 | $15.06M | +128.2% | — | — | |
| LTM Mar 2026 | $11.46M | +137.7% | — | — | |
| LTM Mar 2026 | $7.95M | +1427.0% | -64.7% | 138.5% | |
| LTM Mar 2026 | $7.71M | +65.2% | +43.6% | 10.8% | |
| Peer median (excluding SGMT) | $7.83M | +96.7% | -21.8% | 116.0% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 1.88M | 4.99M | 5.29M | 6.45M |
| Change in Working Capital | (55K) | 4.21M | (978K) | (1.05M) | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 120K | (907K) | 929K |
| Other Working Capital | (55K) | 4.21M | (1.1M) | (141K) | (1.98M) |
| Other Non-Cash Items | 883K | (215K) | 98K | (1.11M) | (8K) |
| Operating Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (41.45M) | (19.62M) | (108.09M) | (106.86M) |
| Sales of Investments | 0 | 9.44M | 32.2M | 46.4M | 111.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (32.01M) | 12.58M | (61.68M) | 4.56M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 12K | 89.68M | 105.75M | 275K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.07M) | (85K) | (3.51M) | (931K) | 0 |
| Financing Cash Flow | 9.74M | (73K) | 86.17M | 104.82M | 275K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.97M) | (56.57M) | 74.98M | 701K | (40.82M) |
| Free Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.